Free tool
FAERS Monitor: Sustol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022445 or its brand name (Sustol, Granisetron). Reports on generic versions are filed under their own applications.
Reports
8,930
Serious
8,044
90% of reports
Hospitalization
4,797
Death reported
1,558
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,069
- febrile neutropenia724
- vomiting673
- diarrhoea665
- pyrexia622
- dyspnoea580
- fatigue508
- anaemia471
- neutropenia461
- off label use440
- death346
- general physical health deterioration346
- pneumonia346
- constipation343
- decreased appetite340
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 129 |
| 2005 | 106 |
| 2006 | 60 |
| 2007 | 74 |
| 2008 | 63 |
| 2009 | 53 |
| 2010 | 123 |
| 2011 | 242 |
| 2012 | 621 |
| 2013 | 366 |
| 2014 | 421 |
| 2015 | 431 |
| 2016 | 654 |
| 2017 | 568 |
| 2018 | 701 |
| 2019 | 619 |
| 2020 | 603 |
| 2021 | 721 |
| 2022 | 680 |
| 2023 | 481 |
| 2024 | 441 |
| 2025 | 476 |
| 2026 | 296 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,229 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 724 | 26.0 | 24.2 | 17,229 |
| neutropeniaSignal | 461 | 8.0 | 7.3 | 2,830 |
| general physical health deteriorationSignal | 346 | 7.1 | 6.4 | 1,799 |
| anaemiaSignal | 471 | 5.8 | 5.3 | 1,892 |
| pyrexiaSignal | 622 | 4.2 | 3.9 | 1,559 |
| constipationSignal | 343 | 3.7 | 3.3 | 682 |
| decreased appetiteSignal | 340 | 3.5 | 3.1 | 595 |
| vomitingSignal | 673 | 3.4 | 3.1 | 1,146 |
| nauseaSignal | 1,069 | 3.2 | 3.0 | 1,660 |
| pneumoniaSignal | 346 | 2.5 | 2.3 | 320 |
| diarrhoeaSignal | 665 | 2.4 | 2.3 | 574 |
| dyspnoeaSignal | 580 | 2.4 | 2.2 | 492 |
| fatigue | 508 | 1.5 | 1.4 | 98 |
| off label use | 440 | 1.2 | 1.1 | 13 |
| death | 346 | 0.9 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.